Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)